JBIO
Price
$7.86
Change
-$0.22 (-2.72%)
Updated
Aug 29, 04:05 PM (EDT)
Capitalization
263.62M
KNSA
Price
$33.37
Change
-$0.13 (-0.39%)
Updated
Aug 29, 04:06 PM (EDT)
Capitalization
2.48B
67 days until earnings call
Interact to see
Advertisement

JBIO vs KNSA

Header iconJBIO vs KNSA Comparison
Open Charts JBIO vs KNSABanner chart's image
Jade Biosciences
Price$7.86
Change-$0.22 (-2.72%)
Volume$100
Capitalization263.62M
Kiniksa Pharmaceuticals International
Price$33.37
Change-$0.13 (-0.39%)
Volume$132
Capitalization2.48B
JBIO vs KNSA Comparison Chart in %
Loading...
JBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
KNSA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
JBIO vs. KNSA commentary
Aug 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is JBIO is a StrongBuy and KNSA is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 29, 2025
Stock price -- (JBIO: $8.08 vs. KNSA: $33.50)
Brand notoriety: JBIO and KNSA are both not notable
JBIO represents the Biotechnology, while KNSA is part of the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: JBIO: 22% vs. KNSA: 31%
Market capitalization -- JBIO: $263.62M vs. KNSA: $2.48B
JBIO [@Biotechnology] is valued at $263.62M. KNSA’s [@Pharmaceuticals: Generic] market capitalization is $2.48B. The market cap for tickers in the [@Biotechnology] industry ranges from $100.52B to $0. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $68.6B to $0. The average market capitalization across the [@Biotechnology] industry is $1.84B. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.84B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

JBIO’s FA Score shows that 1 FA rating(s) are green whileKNSA’s FA Score has 0 green FA rating(s).

  • JBIO’s FA Score: 1 green, 4 red.
  • KNSA’s FA Score: 0 green, 5 red.
According to our system of comparison, both JBIO and KNSA are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

JBIO’s TA Score shows that 4 TA indicator(s) are bullish while KNSA’s TA Score has 5 bullish TA indicator(s).

  • JBIO’s TA Score: 4 bullish, 6 bearish.
  • KNSA’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, KNSA is a better buy in the short-term than JBIO.

Price Growth

JBIO (@Biotechnology) experienced а +9.49% price change this week, while KNSA (@Pharmaceuticals: Generic) price change was -0.24% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.74%. For the same industry, the average monthly price growth was +15.52%, and the average quarterly price growth was +29.97%.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +1.25%. For the same industry, the average monthly price growth was +68.20%, and the average quarterly price growth was +81.63%.

Reported Earning Dates

KNSA is expected to report earnings on Nov 04, 2025.

Industries' Descriptions

@Biotechnology (-0.74% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

@Pharmaceuticals: Generic (+1.25% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
KNSA($2.48B) has a higher market cap than JBIO($264M). JBIO YTD gains are higher at: 204.906 vs. KNSA (69.363). KNSA has more cash in the bank: 308M vs. JBIO (221M). JBIO has less debt than KNSA: JBIO (792K) vs KNSA (9.77M).
JBIOKNSAJBIO / KNSA
Capitalization264M2.48B11%
EBITDAN/A5.98M-
Gain YTD204.90669.363295%
P/E RatioN/A670.00-
RevenueN/A529M-
Total Cash221M308M72%
Total Debt792K9.77M8%
FUNDAMENTALS RATINGS
KNSA: Fundamental Ratings
KNSA
OUTLOOK RATING
1..100
25
VALUATION
overvalued / fair valued / undervalued
1..100
96
Overvalued
PROFIT vs RISK RATING
1..100
50
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
39
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
90

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
JBIOKNSA
RSI
ODDS (%)
Bullish Trend 2 days ago
86%
Bearish Trend 2 days ago
89%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
79%
Momentum
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
84%
MACD
ODDS (%)
Bullish Trend 2 days ago
87%
Bearish Trend 2 days ago
78%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
84%
Bearish Trend 2 days ago
79%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
76%
Advances
ODDS (%)
Bullish Trend 8 days ago
81%
Bullish Trend 3 days ago
74%
Declines
ODDS (%)
Bearish Trend 10 days ago
90%
N/A
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
79%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
75%
View a ticker or compare two or three
Interact to see
Advertisement
JBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
KNSA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RMYCX9.800.01
+0.10%
Russell Inv Multi-Strategy Income C
CDGCX15.27N/A
N/A
Crawford Large Cap Dividend C
JRBFX30.80N/A
N/A
JHancock Regional Bank I
PEOPX63.83N/A
N/A
BNY Mellon S&P 500 Index
PAFDX37.50N/A
N/A
T. Rowe Price Equity Income Advisor

JBIO and

Correlation & Price change

A.I.dvisor indicates that over the last year, JBIO has been closely correlated with OVID. These tickers have moved in lockstep 79% of the time. This A.I.-generated data suggests there is a high statistical probability that if JBIO jumps, then OVID could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To JBIO
1D Price
Change %
JBIO100%
+1.64%
OVID - JBIO
79%
Closely correlated
-0.79%
KNSA - JBIO
37%
Loosely correlated
-0.59%
SYRE - JBIO
30%
Poorly correlated
-2.45%
KPRX - JBIO
29%
Poorly correlated
-2.80%
MAIA - JBIO
26%
Poorly correlated
-7.88%
More

KNSA and

Correlation & Price change

A.I.dvisor indicates that over the last year, KNSA has been loosely correlated with COYA. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if KNSA jumps, then COYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KNSA
1D Price
Change %
KNSA100%
-0.59%
COYA - KNSA
42%
Loosely correlated
+2.29%
ABVC - KNSA
40%
Loosely correlated
+3.36%
JBIO - KNSA
37%
Loosely correlated
+1.64%
AMRN - KNSA
36%
Loosely correlated
-0.42%
CPRX - KNSA
36%
Loosely correlated
+0.94%
More